Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
PHA121 is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist. Data from Phase 1 studies in healthy volunteers demonstrate rapid exposure and predictable linear pharmacokinetics, and inhibition of bradykinin-induced hemodynamic changes in a human bradykinin-challenge study. PHVS416, a softgel capsule formulation containing PHA121, is currently in Phase 2 clinical development for the on-demand treatment of HAE.
Pharvaris was founded in October 2015 by executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
Mar 04, 2021Pharvaris to Participate in BioCapital Europe
Feb 26, 2021Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE
Feb 19, 2021Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting
More events are coming soon.